Keyphrases
Angiotensin-converting Enzyme Inhibition
100%
Myocardial Infarction
100%
Trandolapril
100%
Cardiac Evaluation
100%
Relative Risk
44%
Infarction
33%
Treatment Group
22%
Placebo
22%
All-cause Mortality
11%
Dose Titration
11%
Reduced Mortality
11%
Reduced Systolic Function
11%
Non-fatal
11%
Sudden Death
11%
Reduced Left Ventricular Function
11%
Ejection Fraction
11%
Long-term Treatment
11%
Recurrent Myocardial Infarction
11%
Cardiovascular Mortality
11%
Consecutive Patients
11%
Heart Failure
11%
Clinical Practice
11%
Echocardiographic
11%
Left Ventricular Systolic Dysfunction
11%
Angiotensin-converting Enzyme Inhibitor (ACEi)
11%
Relative Risk Reduction
11%
Placebo Groups
11%
Left Ventricular Dysfunction
11%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
100%
Dipeptidyl Carboxypeptidase
100%
Trandolapril
100%
Enzyme Inhibition
100%
Placebo
33%
Infarction
33%
Treatment Group
22%
Left Ventricular Systolic Dysfunction
11%
All Cause Mortality
11%
Dipeptidyl Carboxypeptidase Inhibitor
11%
Sudden Death
11%
Heart Left Ventricle Failure
11%
Congestive Heart Failure
11%